IBC's Oligonucleotide and Peptide(R) Technology and Product Development
Posted on: Friday, 15 February 2008, 09:01 CST
IBC's TIDES: Oligonucleotide and Peptide(R) Technology and Product Development 2008, to be held May 19-21, 2008, is returning to the Red Rock Casino, Resort and Spa in Las Vegas, Nevada once again. The conference is designed to provide industry updates on developments on regulatory pathways, business landscape, analytical methods and validation, and emerging technologies. It is the only forum that covers manufacturing, formulation, delivery, process and analytical development and overall market trends for peptide- and oligonucleotide-based therapeutics and diagnostics.
2008 Keynote and Feature Presentations:
-- FDA's Current Expectations on the Chemistry, Manufacturing and Controls of Peptide- and Oligonucleotide- Based Therapeutics Blair A. Fraser, Ph.D., Director, Division of Pre-Marketing Assessment I, Office of New Drug Quality Assessment, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration -- Merck's Perspective on siRNA as a Therapeutic Modality Alan Sachs, M.D., Ph.D., Vice President, RNA Therapeutics, Merck Research Laboratories -- Opportunities and Challenges of Developing Peptide Drugs in the Pharmaceutical Industry Waleed Danho, Ph.D., Distinguished Research Leader, Discovery Chemistry, Hoffmann-LaRoche Inc. -- Toward a Non Coding RNA Revolution in the Cancer Society George A. Calin, M.D., Ph.D., Associate Professor, Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center -- What Can Molecular Profiling Tell us About the Specificity of RNA Therapeutics? Aimee Jackson, Ph.D., Senior Research Fellow, Molecular Profiling, Rosetta Inpharmatics, LLC., a wholly owned subsidiary of Merck & Co., Inc. -- Companion Diagnostics: The Future Is Near Larry Gold, Ph.D., CEO and Chairman, SomaLogic, Inc.
IBC's TIDES(R) Conference provides strategies for economical and regulatory compliant production of peptides and oligonucleotides for therapeutics, diagnostics and research and development strategies. Thirteen case studies will be offered in addition to the 28 scientific sessions which include over 100 presentations. Attendees will have the option to pre-arrange onsite meetings with the new partnering system debuting this year.
This conference is co-located with Nucleic Acids Technologies for Diagnostics, a forum for suppliers and end-users to forge collaborations and discuss the technological, regulatory, operational and business considerations surrounding the manufacturing of IVD's.
For more information and to register for this conference please visit, http://www.IBCLifeSciences.com/diagnostics.
CONTACT: Kerry Patterson EMAIL: Email Contact
SOURCE: IBC Life Sciences
Source: MARKET WIRE
Related Articles
- Advanced Energy to Webcast Presentation at the Citi Investment Research Technology Conference
- Google to Present at the Citi Investment Research Technology Conference
- Tumor Targeting Docetaxel Abstract Presented at the 11th Liposome Research Days Conference
- Tumor Targeting Docetaxel Abstract Selected for Presentation at the 11th Liposome Research Days Conference
- NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
- New Report Examines Emerging Therapeutic, Diagnostic and Market Opportunities in the Area of Cancer Stem Cell Research
- The African Medical and Research Foundation (AMREF) Honors Merck & Co., Inc. With Global Corporate Philanthropy Award
- Vyteris Announces Positive Results in Two Phase I Clinical Trials for Treatment of Infertility; Data Indicate Actyve(TM) Transdermal Drug Delivery Achieves Therapeutic Levels Of A Peptide Used For Treatment Of Infertility In Humans
- Dyax Corp. And Merck KGaA Enter Into License Agreement for Discovery of Therapeutic Antibodies and Peptides
- Researchers Tested AIDS Drugs on Children
 |
 |
User Comments (0)
RSS Feeds